Advent Technologies signs MoU With Saudi-Based Company, Hydrogen Systems, Inc. To Distribute Fuel Cells And Hydrogen Products In The Middle East

Advent Technologies Holdings, Inc. (NASDAQ:ADN) (“Advent“ or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced it has signed a Memorandum

Advent Technologies Holdings, Inc. (NASDAQ:ADN) (“Advent“ or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced it has signed a Memorandum of Understanding (“MoU”) with Hydrogen Systems, Inc. (“Hydrogen Systems”), a hydrogen energy solutions company based in Riyadh, Saudi Arabia, to provide integrated hydrogen solutions and value-added support to industrial and renewable energy markets in the Middle East.

Under the MoU, Hydrogen Systems aims to utilize a vast number of existing relationships in the telecom and hydrogen energy marketplace in the Kingdom of Saudi Arabia, and elsewhere throughout the Middle East to market, sell, distribute, install and service Advent’s full line of high-temperature proton exchange membrane (“HT-PEM”) fuel cells and hydrogen production products. Simultaneously, Advent and Hydrogen Systems intend to collaborate and explore potential large-scale development opportunities for hydrogen fuel cell power applications across the region.

Advent’s family of products, including the Serene and M-ZERØ® fuel cell systems, realize a significant carbon advantage over conventional diesel remote power generation technology. HT-PEM fuel cells can operate with a range of low or zero-carbon hydrogen fuels and enable more efficient heat management. Such fuel cells can produce power in extreme ambient temperatures (from -40°C to up to +55°C) and conditions such as high air pollution and low humidity, resulting in a longer lifetime and lower total cost of ownership.

Total
0
Shares
Related Posts
Read More

Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies; Gilead Will Pay Macrogenics An Upfront Payment Of $60M And MacroGenics Will Be Eligible To Receive Up To $1.7B In Potential Milestones

Gilead Sciences, Inc. (NASDAQ:GILD) and MacroGenics (NASDAQ:MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using

GILD